Rivaroxaban is as effective as controls for DVT/PE prevention following bariatric surgery, although minor and major bleeding requiring transfusion are more common.
Meta-Analysis
Does rivaroxaban safely and effectively prevent DVT/PE compared to controls in patients following bariatric surgery?
Rivaroxaban is an effective alternative for VTE prophylaxis after bariatric surgery, offering comparable efficacy to controls despite a higher incidence of bleeding.
Abstract Bariatric surgery and obesity increase VTE risk. While VTE incidence after bariatric surgery is low, it impacts morbidity and 30-day mortality. The lack of consensus on the optimal thromboprophylaxis has driven research into alternatives like DOACs. The objective of this study is to determine the efficacy and safety of rivaroxaban as thromboprophylaxis after bariatric surgery and the most effective thromboprophylaxis strategy. Findings from the nine included studies show that rivaroxaban is as effective as controls for DVT/PE prevention, with no PMVT cases. The incidence of minor and major bleeding requiring transfusion are more common with rivaroxaban however the meta-analysis does not consider this as significant evidence against its use. In the subgroup analysis, no significant differences are observed between long- and short-course rivaroxaban regimens across all primary outcomes, though shorter courses showed fewer bleeding complications.
Catania et al. (Wed,) conducted a meta-analysis in Bariatric surgery. Rivaroxaban vs. Controls was evaluated on DVT/PE prevention. Rivaroxaban is as effective as controls for DVT/PE prevention following bariatric surgery, although minor and major bleeding requiring transfusion are more common.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: